Suchergebnisse - "F0P408N6V4"

PubPharm (3.679)

101

Personalized Medicine's Coming of Age : One Drug, One Patient

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Qazilbash, M. | Kwak, L.

CommentOn: Clin Cancer Res. 2023 Dec 1;29(23):4784-4796. - PMID 37463058

102

Treatment of lower risk myelodysplastic syndromes

enthalten in: Bulletin du cancer | 2023

von Park, S.

103

Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Loncharich, A. | Fiala, M. | Slade, M. | +7

104

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients : a single centre experience from the GMMG-HD6 and -HD7 trials

enthalten in: BMC cancer | 2023

von Kauer, J. | Freundt, E. | Schmitt, A. | +7

105

Inhalation Lenalidomide-Loaded Liposome for Bleomycin-Induced Pulmonary Fibrosis Improvement

enthalten in: AAPS PharmSciTech | 2023

von Luo, Z. | Ji, L. | Liu, H. | +6

106

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma

enthalten in: Blood advances | 2023

von Yamshon, S. | Chen, G. | Gribbin, C. | +9

107

A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Davies, F. | Leleu, X. | Vogel, P. | +3

108

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma : a study on behalf of the Chronic malignancies working party of the EBMT

enthalten in: Bone marrow transplantation | 2023

von Tilmont, R. | Yakoub-Agha, I. | Eikema, D. | +23

109

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

enthalten in: Blood | 2023

von Rosiñol, L. | Oriol, A. | Ríos, R. | +26

CommentIn: Blood. 2023 Nov 2;142(18):1501-1502. - PMID 37917081

110

Maintain maintenance in multiple myeloma?

enthalten in: Blood | 2023

von Zweegman, S. | van de Donk, N.

CommentOn: Blood. 2023 Nov 2;142(18):1518-1528. - PMID 37506339